This poster and the accompanying short video describe some preliminary results of a budget impact analysis using data from the Cluster Randomised Trial of Testing for Prostate Cancer study (CAP). We examined secondary care costs in the first year post-randomisation for men randomised to receive a single PSA screening invitation alongside usual care, and compared them with secondary care costs for men randomised to receive usual care only.